<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1886">
  <stage>Registered</stage>
  <submitdate>17/03/2008</submitdate>
  <approvaldate>17/03/2008</approvaldate>
  <nctid>NCT00640523</nctid>
  <trial_identification>
    <studytitle>Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)</studytitle>
    <scientifictitle>Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>BCX1777-210</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Lymphocytic Leukemia (CLL)</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - forodesine HCl

Treatment: drugs: forodesine HCl
2 x 100mg capsules daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Overall response rate</outcome>
      <timepoint>Up to 6 cycles of therapy</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Age 18 years and older

          2. Diagnosis of CLL established by peripheral blood and/or bone marrow examination and
             using the standard diagnostic criteria.

          3. Subjects with Rai stage III or IV, or earlier stage requiring therapy as determined by
             the 1996 National Cancer Institute -Working Group (NCI-WG) criterion

          4. Primary resistant (no CR or PR) or progressive disease after response to at least one
             prior treatment regimen OR treatment naïve subjects who meet at least one of the
             following criteria.

               1. age &gt;65 years

               2. Eastern Cooperative Oncology Group (ECOG) performance status of 2, 3, or 4

               3. Inability to tolerate standard cytotoxic chemotherapy in the opinion of the
                  treating physician.

          5. ECOG performance status of 0, 1, or 2 (for subjects with primary resistance or
             progressive disease after response to at least one prior treatment regimen).

          6. Willing to take adequate contraceptive measures (i.e., latex condom, cervical cap,
             diaphragm, abstinence, etc.) for the entire duration of the study and 3 months after,
             except for patients who are post menopausal or have prior hysterectomy.

          7. All investigational treatments should have been discontinued for at least 3 weeks
             prior to the initiation of the study drug.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Pregnant or nursing.

          2. Unable or unwilling to sign consent.

          3. Severe, ongoing co-morbid conditions, which would preclude safe delivery of the
             investigational therapy.

          4. Active serious infections that are not controlled by antibiotics.

          5. ECOG performance status &gt;2 (except for treatment naïve subjects where ECOG performance
             status 0, 1 or 5 is excluded).

          6. Inadequate renal function: creatinine &gt; or equal to 2.0 unless related to the disease.

          7. Inadequate liver function: bilirubin &gt; or equal to 3.0; transaminases &gt; or equal to
             3.0 times the upper limit of normal unless related to the disease.

          8. Known positive test for human immunodeficiency virus (HIV).

          9. Subjects with known hepatitis B and/or hepatitis C active infection.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>23</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,VIC</recruitmentstate>
    <hospital>Royal Brisbane and Women's Hospital - Brisbane</hospital>
    <hospital>Frankston Hospital - Frankston</hospital>
    <hospital>Cabrini Hospital - Malvern</hospital>
    <postcode>4029 - Brisbane</postcode>
    <postcode>3199 - Frankston</postcode>
    <postcode>3144 - Malvern</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>BioCryst Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To evaluate the effectiveness and safety of forodesine in CLL patients</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00640523</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Asher Chanan-Khan, MD</name>
      <address>Roswell Park Cancer Institute</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>